Related Experiment Video

Updated: Jul 24, 2026

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

Biomarker profiles and their relation to clinical variables in mild cognitive impairment

S N M Schoonenboom1, P J Visser, C Mulder

  • 1Department of Neurology Alzheimer Centre, VU University Medical Centre, Amsterdam, the Netherlands. niki.schoonenboom@vumc.nl

Neurocase
|April 5, 2005
PubMed

Insights

Patients with mild cognitive impairment (MCI) at high or intermediate risk for Alzheimer's disease (AD) showed differences in cognitive functions and preclinical AD scale scores compared to low-risk individuals. Biomarker levels correlated with clinical markers, suggesting interconnectedness.

Area of Science:

  • Neuroscience
  • Biomarkers
  • Alzheimer's Disease Research

Background:

  • Mild cognitive impairment (MCI) is a transitional stage between normal aging and Alzheimer's disease (AD).
  • Biomarker profiles in cerebrospinal fluid (CSF) can stratify MCI patients by AD risk.
  • Understanding clinical differences across risk groups is crucial for early intervention.

Purpose of the Study:

  • To compare clinical variables in MCI patients stratified by Alzheimer's disease (AD) risk based on CSF biomarker profiles.
  • To investigate the relationship between CSF biomarkers (Abeta42, tau) and clinical assessments in MCI.

Main Methods:

  • Cerebrospinal fluid (CSF) analysis for amyloid-beta 42 (Abeta42) and tau levels.
  • Classification of 39 MCI patients into high-risk (low Abeta42/high tau), intermediate-risk (abnormal single biomarker), and low-risk (normal biomarkers) groups.
  • Comparison of cognitive functions (episodic memory, executive functions) and the preclinical AD scale (PAS) across risk groups.

Main Results:

  • Fifty-four percent of MCI patients were classified as high-risk, 26% as intermediate-risk, and 20% as low-risk.
  • Both high-risk and intermediate-risk groups exhibited significant differences in episodic memory, executive functions, and PAS scores compared to the low-risk group.
  • No significant differences were observed between the high-risk and intermediate-risk groups.
  • Abeta42 levels correlated with MTA and PAS scores; tau levels correlated with episodic memory.

Conclusions:

  • CSF biomarker profiles effectively differentiate MCI patients with varying risks for Alzheimer's disease.
  • Clinical manifestations, including cognitive performance and preclinical AD markers, align with AD risk stratification.
  • The correlations between biomarkers and clinical/neuropsychological markers suggest their interdependence, warranting further longitudinal investigation.

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...